Trial Profile
Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CARMENA
- 04 Jun 2019 Results assessing different subgroups from the Carmena trial in patients with metastatic renal cell carcinoma presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 02 Aug 2018 Results published in the Urology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology